Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

Conditions:   Relapsing Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis Interventions:   Drug: Rituximab;   Drug: Ocrelizumab;   Drug: Fexofenadine;   Drug: Paracetamol;   Drug: Methylprednisolone Sponsors:   Rigshospitalet, Denmark;   Odense University Hospital;   Aarhus University Hospital;   Aalborg University Hospital;   Herlev Hospital;   Hillerod Hospital, Denmark;   Zealand University Hospital;   Kolding Sygehus;   Regional Hospital Holstebro;   Hvidovre University Ho spital;   Hospital of South West Jutland, Esbjerg, Denmark;   GCP unit, Copenhagen University Hospital;   GCP-unit at Aarhus University Hospital, Aarhus, Denmark;   Hospital of Southern Jutland, Sønderborg, Denmark;   Hospital of Central Denmark Region, Viborg, Denmark;   Dansk e Regioner;   GCP unit Odense University Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials